Gold prices edge lower; heading for weekly losses ahead of U.S.-Russia talks
LONDON - Creo Medical (TASE:BLWV) Group plc (AIM:CREO) reported that a patient successfully underwent treatment using its Speedboat technology, avoiding a full bowel resection that would have been otherwise required.
The patient, Liz Thomas, who is the wife of a retired Creo software engineer who helped develop the technology, was diagnosed with a health condition in late 2024. Initially, she was told her only treatment option was a full bowel resection as the Speedboat procedure was not available through NHS Wales at that time.
After seeking a second opinion, Thomas opted for private treatment in England where she received the Speedboat procedure as an outpatient. According to the company’s press release, she recovered and returned to daily activities within days of the procedure.
The company stated that the Speedboat device was used to remove a 5cm pre-cancerous lesion without stitches, scarring, or the need for prolonged recovery.
In February 2025, Aneurin Bevan University Health Board became the first in Wales to pilot Creo’s Speedboat technology. The company reports that Welsh patients have already been treated with the device since early 2025.
Creo Medical, based in Wales, focuses on minimally invasive surgical endoscopy for pre-cancer and cancer patients. The company claims its technology can reduce surgical burden, shorten hospital stays, and improve patient outcomes.
The information in this article is based on a press release statement from Creo Medical Group.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.